Drug Innovation
Commentary
Trump wrongly attacks life-saving drug companies on coronavirus vaccines and more
President Trump announced Friday that he will proceed with his plans to peg the prices of certain drugs prescribed largely at doctors’ offices under Medicare Part B to the lower prices that other developed nations pay for those drugs. That may sound good at first glance, but in reality, the move will slow ...
Drug Importation
NEW BRIEF: Counterfeit Drugs Harm Patients, Economy, Innovation
A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute shows that counterfeit drugs put patients in harm’s way, hinder drug innovation, and lead to job losses. Proposals like drug importation or price controls, if implemented, would exacerbate the problem and ...
Commentary
Price Controls Are Disastrous For Rents And Will Be For Drugs
President Trump and senior advisor Jared Kushner claim that the most favored nation executive order signed by the President over the weekend is necessary for drug pricing because “the U.S. shouldn’t pay more than other European countries for the same treatments.” This policy will make things worse, not better. If the president ...
Commentary
President Trump’s Big Government Instincts Threaten Drug Innovation And Availability
President Reagan famously said, “the nine most terrifying words in the English language are: I’m from the Government and I’m here to help”. It is time for President Trump to learn this wisdom. Along with Speaker Pelosi, Senator Sanders, and Representative Ocasio-Cortez, President Trump seems to believe that giving the ...
Commentary
Patients Will Suffer The Most From The Trump Administration’s Reference Pricing Scheme
The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And, ...
Blog
What We’re Watching – Good Friday Edition
Tim Anaya – The Crossroads of Innovation and Affordability In the latest “Escape the Drug Pricing Maze” video, On the first step toward escaping the Drug Pricing Maze, Professor Salvare takes Pete Paystoomuch down the path of drug innovation, showing him why drug prices are initially more expensive – to ...
Drug Innovation
Sally C. Pipes Discusses Changing Drug Regulations on the Lars Larson Show
Sally C. Pipes joins the Lars Larson Show on KXL to discuss how new regulations will change drug prices in Canada and discourage drug innovation.
Commentary
Don’t Slash Medicare In Last – Minute Budget Agreement
The weather isn’t the only thing heating up in Washington. White House officials are feverishly negotiating with congressional leaders to raise the debt ceiling and reach a two-year budget deal that averts more than $126 billion in automatic spending cuts. Democrats want the deal to dramatically raise domestic spending levels. Republicans ...
Drug Innovation
Wayne Winegarden Biosimilar Study Featured in Fierce Healthcare
Report: Growing biosimilar market could save billions in health spending By Paige Minemyer Growing the biosimilar market could lead to significant healthcare cost savings, according to a new report, with the opportunity for billions in cost reductions. An analysis (PDF) from the Pacific Research Institute, a free market think tank, shows today ...
Drug Innovation
PRI’s biosimilars study featured in Politico’s Prescription Pulse newsletter
The Pacific Research Institute’s Center for Medical Economics and Innovation study on biosimilars was published in Politico’s Prescription Pulse newsletter.
Trump wrongly attacks life-saving drug companies on coronavirus vaccines and more
President Trump announced Friday that he will proceed with his plans to peg the prices of certain drugs prescribed largely at doctors’ offices under Medicare Part B to the lower prices that other developed nations pay for those drugs. That may sound good at first glance, but in reality, the move will slow ...
NEW BRIEF: Counterfeit Drugs Harm Patients, Economy, Innovation
A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute shows that counterfeit drugs put patients in harm’s way, hinder drug innovation, and lead to job losses. Proposals like drug importation or price controls, if implemented, would exacerbate the problem and ...
Price Controls Are Disastrous For Rents And Will Be For Drugs
President Trump and senior advisor Jared Kushner claim that the most favored nation executive order signed by the President over the weekend is necessary for drug pricing because “the U.S. shouldn’t pay more than other European countries for the same treatments.” This policy will make things worse, not better. If the president ...
President Trump’s Big Government Instincts Threaten Drug Innovation And Availability
President Reagan famously said, “the nine most terrifying words in the English language are: I’m from the Government and I’m here to help”. It is time for President Trump to learn this wisdom. Along with Speaker Pelosi, Senator Sanders, and Representative Ocasio-Cortez, President Trump seems to believe that giving the ...
Patients Will Suffer The Most From The Trump Administration’s Reference Pricing Scheme
The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And, ...
What We’re Watching – Good Friday Edition
Tim Anaya – The Crossroads of Innovation and Affordability In the latest “Escape the Drug Pricing Maze” video, On the first step toward escaping the Drug Pricing Maze, Professor Salvare takes Pete Paystoomuch down the path of drug innovation, showing him why drug prices are initially more expensive – to ...
Sally C. Pipes Discusses Changing Drug Regulations on the Lars Larson Show
Sally C. Pipes joins the Lars Larson Show on KXL to discuss how new regulations will change drug prices in Canada and discourage drug innovation.
Don’t Slash Medicare In Last – Minute Budget Agreement
The weather isn’t the only thing heating up in Washington. White House officials are feverishly negotiating with congressional leaders to raise the debt ceiling and reach a two-year budget deal that averts more than $126 billion in automatic spending cuts. Democrats want the deal to dramatically raise domestic spending levels. Republicans ...
Wayne Winegarden Biosimilar Study Featured in Fierce Healthcare
Report: Growing biosimilar market could save billions in health spending By Paige Minemyer Growing the biosimilar market could lead to significant healthcare cost savings, according to a new report, with the opportunity for billions in cost reductions. An analysis (PDF) from the Pacific Research Institute, a free market think tank, shows today ...
PRI’s biosimilars study featured in Politico’s Prescription Pulse newsletter
The Pacific Research Institute’s Center for Medical Economics and Innovation study on biosimilars was published in Politico’s Prescription Pulse newsletter.
